These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2501273)

  • 21. The penetration of fleroxacin into intra-abdominal abscesses.
    Youngs DJ; Tudor RG; Yoshioka K; Keighley MR
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():115-8. PubMed ID: 3144528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid transcription factor-1 expression in normal gynecologic tissues and its potential significance.
    Niu HL; Pasha TL; Pawel BR; LiVolsi VA; Zhang PJ
    Int J Gynecol Pathol; 2009 Jul; 28(4):301-7. PubMed ID: 19483637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
    Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic implications of doxycycline and cephalothin concentrations in the female genital tract.
    Whelton A; Blanco LJ; Carter GG; Craig TJ; Bryant HH; Herbst DV; King TM
    Obstet Gynecol; 1980 Jan; 55(1):28-32. PubMed ID: 7352059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of free tissue concentrations of fleroxacin after oral administration.
    Limberg J; LeBel M; Derendorf H
    Pharm Res; 1990 Apr; 7(4):422-4. PubMed ID: 2114021
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
    Hoogkamer JF; Kleinbloesem CH
    Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
    [No Abstract]   [Full Text] [Related]  

  • 31. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetration of pefloxacin into gynaecological tissues.
    Bouvet O; Bressolle F; Courtieu C; Galtier M
    J Antimicrob Chemother; 1992 May; 29(5):579-87. PubMed ID: 1624396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
    Kees F; Naber KG; Schumacher H; Grobecker H
    Chemotherapy; 1988; 34(6):437-43. PubMed ID: 2468456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effect of fleroxacin against experimental pneumonia in mice.
    Niki Y; Watanabe M; Tasaka Y; Umeki S; Soejima R
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():129-31. PubMed ID: 3144531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
    Hummler H; Richter WF; Hendrickx AG
    Toxicol Appl Pharmacol; 1993 Sep; 122(1):34-45. PubMed ID: 8397453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of fleroxacin on HeLa cell functions and topoisomerase II.
    Oomori Y; Yasue T; Aoyama H; Hirai K; Suzue S; Yokota T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():91-7. PubMed ID: 2849603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.
    Whitby M; Angus L; Nimmo G; Hill V
    Chemotherapy; 1996; 42(6):468-72. PubMed ID: 8957583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.